查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971142

伴侶動物疫苗市場分析及預測（至2035年）：類型、產品、技術、應用、最終用戶、功能、服務、部署、材料類型、階段

Companion Animal Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Functionality, Services, Deployment, Material Type, Stage
出版日期: | 出版商: Global Insight Services | 英文 447 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，伴侶動物疫苗市場規模將從2024年的42.2億美元成長至97.9億美元，複合年成長率約為8.8%。市場主要涵蓋寵物（如犬貓）疫苗的研發和分銷，旨在預防狂犬病、犬瘟熱和貓白血病等疾病。寵物飼養量的成長、動物健康意識的提高以及生物技術的進步是推動該市場成長的主要因素。市場關注的重點是提高疫苗的有效性和安全性，其中重組疫苗和DNA疫苗的創新備受矚目。隨著全球獸醫標準的不斷提高，對全面免疫接種計劃的需求持續成長，凸顯了該領域巨大的成長潛力。

受寵物飼養量增加和動物健康意識提升的推動，伴侶動物疫苗市場正經歷強勁成長。犬用疫苗領域佔據主導地位，其中狂犬病和犬瘟熱疫苗尤為重要，這主要歸因於監管要求和疫情的廣泛爆發。貓科動物疫苗領域緊隨其後，隨著人們對貓科動物特有疾病的認知不斷提高，貓白血病和狂犬病疫苗的需求也不斷成長。隨著將牲畜作為寵物飼養的趨勢日益成長，牲畜疫苗正成為一個重要的市場區隔。市場對能夠提供全面保護且方便預防多種疾病的聯合疫苗的需求不斷增加。注射疫苗因其高效性和易用性而佔據市場主導地位，但經鼻吸入型疫苗因其非侵入性給藥方式和快速免疫反應而越來越受歡迎。疫苗研發領域的技術進步，例如重組DNA技術，正在提高疫苗的有效性和安全性，為市場擴張提供了廣闊的前景。醫療保健趨勢也進一步推動了市場成長。

市場區隔
種類 減毒活病毒疫苗、去活化疫苗、重組疫苗、類毒素疫苗、結合疫苗、次單位疫苗、DNA疫苗
產品 犬用疫苗、貓疫苗、馬類疫苗
科技 重組DNA技術、細胞培養技術
目的 狂犬病、犬瘟熱、犬細小病毒、鉤端螺旋體病、貓白血病、馬流感
最終用戶 動物醫院、研究機構
功能 預防性疫苗，治療性疫苗
服務 疫苗接種服務、諮詢服務
發展 本機部署、雲端部署
材料類型 生物製藥、合成藥物
階段 臨床前研究、臨床試驗、商業化

市場概況：

受消費者偏好變化和寵物健康意識增強的推動，伴侶動物疫苗市場正經歷蓬勃發展。儘管老牌製藥公司佔據了大部分市場佔有率，但新興企業也透過推出創新產品取得了顯著進展。各公司都在努力平衡疫苗的可負擔性和先進配方的需求，因此定價策略競爭仍然激烈。持續的研發投入以滿足多樣化的獸醫需求，促使新產品不斷湧現。注重預防醫學是該市場的顯著特徵，也是推動市場需求的關鍵因素。伴侶動物疫苗市場的競爭異常激烈，主要企業都在利用技術進步來保持競爭優勢。基準分析表明，投資於前沿研究和建立強大分銷網路的公司往往能夠取得更大的成功。監管的影響至關重要，北美和歐洲嚴格的監管準則塑造市場動態。這些法規確保了高標準，並增強了消費者的信心。市場分析表明，儘管監管挑戰仍然存在，但也為差異化和創新提供了機會。寵物主人數量的增加和動物健康意識的提高正在推動市場需求，市場也呈現出成長的跡象。

主要趨勢和促進因素：

受寵物飼養量增加和動物健康意識提升的推動，伴侶動物疫苗市場正經歷強勁成長。一個關鍵趨勢是，市場對具有更廣泛保護作用和更少副作用的先進疫苗的需求不斷成長。這反映出越來越多的飼主對寵物健康更加了解，並積極參與其中。生物技術的進步正在加速新疫苗的研發，提高其有效性和安全性。這些創新對於應對新出現的疾病和適應不斷演變的病原體至關重要。此外，個人化獸醫的趨勢正在加速發展，透過根據個別動物的具體需求客製化疫苗來最佳化健康。同時，監管框架正在加快新疫苗的核准流程，縮短上市時間。鑑於全球對通用感染疾病的日益關注以及對潛在疫情快速反應的需求，這一點尤其重要。新興市場寵物飼養率不斷上升，獸醫基礎設施不斷完善，蘊藏著許多機會。能夠適應不同法規環境並提供具成本效益解決方案的公司有望佔據可觀的市場佔有率。對預防醫學和長期健康益處的重視將確保對伴侶動物疫苗的持續需求。

壓制與挑戰：

目前，伴侶動物疫苗市場面臨許多重大限制與挑戰。其中一個突出的挑戰是疫苗研發和生產高成本，這限制了小規模獸醫診所和寵物飼主獲得疫苗的機會。監管障礙也是一大障礙，新疫苗的核准流程往往漫長而高成本，延緩了疫苗進入市場。此外，由於對疫苗安全性和有效性的錯誤訊息和懷疑態度，寵物飼主對疫苗的猶豫日益加劇。這種猶豫可能導致疫苗接種率下降，並在疾病爆發期間增加寵物的脆弱性。另外，疫苗的保存期限和儲存要求也增加了分銷物流的複雜性和成本，進一步限制了市場發展。最後，應對新出現的和變異的病原體需要持續的研發，這給資源有限且身處快速變化環境中的生產者帶來了挑戰。所有這些挑戰共同阻礙了伴侶動物疫苗市場的成長和擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 減毒活病毒疫苗
    • 去活化疫苗
    • 重組疫苗
    • 類毒素疫苗
    • 結合疫苗
    • 次單位疫苗
    • DNA疫苗
  • 市場規模及預測：依產品分類
    • 犬用疫苗
    • 貓疫苗
    • 馬疫苗
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 細胞培養技術
  • 市場規模及預測：依應用領域分類
    • 狂犬病
    • 犬瘟熱
    • 細小病毒
    • 鉤端螺旋體病
    • 貓白血病
    • 馬流感
  • 市場規模及預測：依最終用戶分類
    • 動物診所
    • 動物醫院
    • 研究機構
  • 市場規模及預測：依功能分類
    • 預防性疫苗
    • 治療性疫苗
  • 市場規模及預測：依服務分類
    • 疫苗接種服務
    • 諮詢服務
  • 市場規模及預測：依市場細分
    • 現場
    • 基於雲端的
  • 市場規模及預測：依材料類型分類
    • 生物製藥
    • 合成
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床試驗
    • 商業化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Boehringer Ingelheim Animal Health
  • Elanco Animal Health
  • Virbac
  • Ceva Sante Animale
  • Vetoquinol
  • Heska Corporation
  • IDEXX Laboratories
  • Zoetis
  • Phibro Animal Health
  • Neogen Corporation
  • Biogenesis Bago
  • Hipra
  • Bioveta
  • Merial
  • MSD Animal Health
  • Bimeda
  • Aratana Therapeutics
  • Dechra Pharmaceuticals
  • Kyoritsu Seiyaku
  • Merial Animal Health
  • Arcaplanet SpA has acquired Merial Italia SpA
  • so the main corporate website you're looking for has changed. You can find information about the company that acquired Merial Italia SpA by visiting：

第9章 關於我們

簡介目錄
Product Code: GIS33077

Companion Animal Vaccines Market is anticipated to expand from $4.22 billion in 2024 to $9.79 billion by 2034, growing at a CAGR of approximately 8.8%. The Companion Animal Vaccines Market encompasses the development and distribution of vaccines for pets, primarily dogs and cats, aimed at preventing diseases such as rabies, distemper, and feline leukemia. This market is driven by increasing pet ownership, rising awareness of animal health, and advancements in biotechnology. The focus is on enhancing vaccine efficacy and safety, with innovations in recombinant and DNA vaccines gaining traction. As veterinary care standards rise globally, the demand for comprehensive immunization programs continues to expand, highlighting significant growth opportunities within this sector.

The Companion Animal Vaccines Market is experiencing robust growth, fueled by rising pet ownership and increased awareness of animal health. The canine vaccines segment leads performance, with rabies and distemper vaccines being particularly essential due to regulatory requirements and widespread prevalence. Feline vaccines follow closely, with feline leukemia and rabies vaccines gaining traction as awareness of feline-specific diseases rises. Livestock vaccines for companion animals are also emerging as a significant sub-segment, driven by the increasing trend of keeping livestock as pets. The demand for combination vaccines is growing, offering convenience and comprehensive protection against multiple diseases. Injectable vaccines dominate the market, favored for their efficacy and ease of administration. However, intranasal vaccines are gaining popularity for their non-invasive application and rapid immune response. Technological advancements in vaccine development, such as recombinant DNA technology, are enhancing vaccine efficacy and safety, presenting lucrative opportunities for market expansion. The trend towards preventive healthcare is further propelling market growth.

Market Segmentation
TypeLive Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Conjugate Vaccines, Subunit Vaccines, DNA Vaccines
ProductCanine Vaccines, Feline Vaccines, Equine Vaccines
TechnologyRecombinant DNA Technology, Cell Culture Technology
ApplicationRabies, Distemper, Parvovirus, Leptospirosis, Feline Leukemia, Equine Influenza
End UserVeterinary Clinics, Animal Hospitals, Research Institutes
FunctionalityProphylactic Vaccines, Therapeutic Vaccines
ServicesVaccination Services, Consultation Services
DeploymentOn-premise, Cloud-based
Material TypeBiologicals, Synthetic
StagePreclinical, Clinical Trials, Commercialized

Market Snapshot:

The Companion Animal Vaccines Market is experiencing dynamic growth, driven by evolving consumer preferences and an increasing awareness of pet health. Market share is predominantly held by established pharmaceutical companies, with emerging players making significant inroads through innovative product launches. Pricing strategies remain competitive, as companies strive to balance affordability with the need for advanced vaccine formulations. New product introductions are frequent, reflecting ongoing research and development efforts aimed at addressing diverse veterinary needs. The market is characterized by a focus on preventive care, which continues to drive demand. Competition in the Companion Animal Vaccines Market is fierce, with major firms leveraging technological advancements to maintain their competitive edge. Benchmarking reveals that companies investing in cutting-edge research and robust distribution networks are particularly successful. Regulatory influences play a critical role, with stringent guidelines in North America and Europe shaping market dynamics. These regulations ensure high standards, fostering trust among consumers. Market analysis indicates that while regulatory challenges persist, they also present opportunities for differentiation and innovation. The market is poised for growth, with increasing pet ownership and rising awareness of animal health fueling demand.

Geographical Overview:

The companion animal vaccines market is witnessing substantial growth across diverse regions, each exhibiting unique growth dynamics. North America leads the market, driven by high pet ownership rates and a strong emphasis on animal health. Increasing adoption of innovative vaccines and government initiatives supporting animal welfare further bolster this region's market position. Europe closely follows, characterized by robust veterinary healthcare infrastructure and a growing awareness of preventive healthcare for pets. Stringent regulatory frameworks also contribute to the demand for high-quality vaccines. In the Asia Pacific, the market is expanding rapidly, propelled by rising disposable incomes and a growing pet population. Countries like China and India are emerging as lucrative markets, with increased investments in veterinary healthcare. Latin America and the Middle East & Africa are also gaining traction. In Latin America, the growing trend of pet humanization is driving the demand for vaccines. Meanwhile, the Middle East & Africa are recognizing the importance of companion animal health, leading to increased investments in veterinary services.

Key Trends and Drivers:

The Companion Animal Vaccines Market is experiencing robust growth due to increased pet ownership and heightened awareness of animal health. A significant trend is the rising demand for advanced vaccines that offer broader protection and fewer side effects. This is driven by pet owners who are more informed and proactive about their pets' health. Technological advancements in biotechnology are fostering the development of novel vaccines, enhancing efficacy and safety. These innovations are crucial as they address emerging diseases and adapt to evolving pathogens. Moreover, the trend towards personalized veterinary medicine is gaining traction, with vaccines being tailored to the specific needs of individual animals, optimizing health outcomes. Furthermore, the regulatory landscape is evolving to support faster approval processes for new vaccines, reducing time-to-market. This is especially pertinent as global concerns over zoonotic diseases rise, prompting a more agile response to potential outbreaks. Opportunities abound in emerging markets where pet adoption rates are climbing, and veterinary infrastructure is expanding. Companies that can navigate diverse regulatory environments and offer cost-effective solutions are poised to capture significant market share. The focus on preventive care and long-term health benefits ensures sustained demand for companion animal vaccines.

Restraints and Challenges:

The Companion Animal Vaccines Market is currently encountering several significant restraints and challenges. A prominent challenge is the high cost associated with vaccine development and production, which limits accessibility for smaller veterinary practices and pet owners. Regulatory hurdles also pose a significant barrier, as the approval process for new vaccines can be lengthy and costly, delaying market entry. Additionally, there is a growing concern about vaccine hesitancy among pet owners, fueled by misinformation and skepticism about vaccine safety and efficacy. This hesitancy can lead to lower vaccination rates and increased vulnerability to disease outbreaks. Furthermore, the market is constrained by the limited shelf life and storage requirements of vaccines, which complicate distribution logistics and increase costs. Lastly, the emergence of new and evolving pathogens requires continuous research and development, straining resources and challenging manufacturers to keep pace with the dynamic landscape. These challenges collectively hinder the growth and expansion of the Companion Animal Vaccines Market.

Key Players:

Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, Ceva Sante Animale, Vetoquinol, Heska Corporation, IDEXX Laboratories, Zoetis, Phibro Animal Health, Neogen Corporation, Biogenesis Bago, Hipra, Bioveta, Merial, MSD Animal Health, Bimeda, Aratana Therapeutics, Dechra Pharmaceuticals, Kyoritsu Seiyaku, Merial Animal Health, Arcaplanet S.p.A. has acquired Merial Italia S.p.A., so the main corporate website you're looking for has changed. You can find information about the company that acquired Merial Italia S.p.A. by visiting:

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Functionality
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Material Type
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Live Attenuated Vaccines
    • 4.1.2 Inactivated Vaccines
    • 4.1.3 Recombinant Vaccines
    • 4.1.4 Toxoid Vaccines
    • 4.1.5 Conjugate Vaccines
    • 4.1.6 Subunit Vaccines
    • 4.1.7 DNA Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Canine Vaccines
    • 4.2.2 Feline Vaccines
    • 4.2.3 Equine Vaccines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Cell Culture Technology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Rabies
    • 4.4.2 Distemper
    • 4.4.3 Parvovirus
    • 4.4.4 Leptospirosis
    • 4.4.5 Feline Leukemia
    • 4.4.6 Equine Influenza
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Veterinary Clinics
    • 4.5.2 Animal Hospitals
    • 4.5.3 Research Institutes
  • 4.6 Market Size & Forecast by Functionality (2020-2035)
    • 4.6.1 Prophylactic Vaccines
    • 4.6.2 Therapeutic Vaccines
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Vaccination Services
    • 4.7.2 Consultation Services
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by Material Type (2020-2035)
    • 4.9.1 Biologicals
    • 4.9.2 Synthetic
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Clinical Trials
    • 4.10.3 Commercialized

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Functionality
      • 5.2.1.7 Services
      • 5.2.1.8 Deployment
      • 5.2.1.9 Material Type
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Functionality
      • 5.2.2.7 Services
      • 5.2.2.8 Deployment
      • 5.2.2.9 Material Type
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Functionality
      • 5.2.3.7 Services
      • 5.2.3.8 Deployment
      • 5.2.3.9 Material Type
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Functionality
      • 5.3.1.7 Services
      • 5.3.1.8 Deployment
      • 5.3.1.9 Material Type
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Functionality
      • 5.3.2.7 Services
      • 5.3.2.8 Deployment
      • 5.3.2.9 Material Type
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Functionality
      • 5.3.3.7 Services
      • 5.3.3.8 Deployment
      • 5.3.3.9 Material Type
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Functionality
      • 5.4.1.7 Services
      • 5.4.1.8 Deployment
      • 5.4.1.9 Material Type
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Functionality
      • 5.4.2.7 Services
      • 5.4.2.8 Deployment
      • 5.4.2.9 Material Type
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Functionality
      • 5.4.3.7 Services
      • 5.4.3.8 Deployment
      • 5.4.3.9 Material Type
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Functionality
      • 5.4.4.7 Services
      • 5.4.4.8 Deployment
      • 5.4.4.9 Material Type
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Functionality
      • 5.4.5.7 Services
      • 5.4.5.8 Deployment
      • 5.4.5.9 Material Type
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Functionality
      • 5.4.6.7 Services
      • 5.4.6.8 Deployment
      • 5.4.6.9 Material Type
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Functionality
      • 5.4.7.7 Services
      • 5.4.7.8 Deployment
      • 5.4.7.9 Material Type
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Functionality
      • 5.5.1.7 Services
      • 5.5.1.8 Deployment
      • 5.5.1.9 Material Type
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Functionality
      • 5.5.2.7 Services
      • 5.5.2.8 Deployment
      • 5.5.2.9 Material Type
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Functionality
      • 5.5.3.7 Services
      • 5.5.3.8 Deployment
      • 5.5.3.9 Material Type
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Functionality
      • 5.5.4.7 Services
      • 5.5.4.8 Deployment
      • 5.5.4.9 Material Type
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Functionality
      • 5.5.5.7 Services
      • 5.5.5.8 Deployment
      • 5.5.5.9 Material Type
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Functionality
      • 5.5.6.7 Services
      • 5.5.6.8 Deployment
      • 5.5.6.9 Material Type
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Functionality
      • 5.6.1.7 Services
      • 5.6.1.8 Deployment
      • 5.6.1.9 Material Type
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Functionality
      • 5.6.2.7 Services
      • 5.6.2.8 Deployment
      • 5.6.2.9 Material Type
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Functionality
      • 5.6.3.7 Services
      • 5.6.3.8 Deployment
      • 5.6.3.9 Material Type
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Functionality
      • 5.6.4.7 Services
      • 5.6.4.8 Deployment
      • 5.6.4.9 Material Type
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Functionality
      • 5.6.5.7 Services
      • 5.6.5.8 Deployment
      • 5.6.5.9 Material Type
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Boehringer Ingelheim Animal Health
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Elanco Animal Health
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Virbac
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Ceva Sante Animale
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vetoquinol
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Heska Corporation
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 IDEXX Laboratories
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Zoetis
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Phibro Animal Health
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Neogen Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Biogenesis Bago
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Hipra
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bioveta
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Merial
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 MSD Animal Health
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bimeda
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Aratana Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Dechra Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Kyoritsu Seiyaku
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Merial Animal Health
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis
  • 8.21 Arcaplanet S.p.A. has acquired Merial Italia S.p.A.
    • 8.21.1 Overview
    • 8.21.2 Product Summary
    • 8.21.3 Financial Performance
    • 8.21.4 SWOT Analysis
  • 8.22 so the main corporate website you're looking for has changed. You can find information about the company that acquired Merial Italia S.p.A. by visiting:
    • 8.22.1 Overview
    • 8.22.2 Product Summary
    • 8.22.3 Financial Performance
    • 8.22.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us